[Therapeutic effect of adipose tissue-derived stem cells on bleomycin-induced mice of scleroderma].

OBJECTIVE: To investigate the effects and mechanisms of adipose-derived stem cells (ADSCs) on bleomycin-induced mice of scleroderma. METHODS: In the study, 24 C57BL/6J female mice were randomly divided into control group, bleomycin(BLM)group, ADSCs (hypodermic injection) group and ADSCs (intravenous injection) group . BLM [2 mg/(kg×d)] was injected into the mice to establish the model of scleroderma. There were 6 mice in each group .The control group mice were injected with normal saline 2 mL/(kg×d) by subcutaneously. The rest of the three groups were injected with BLM. ADSCs groups were injected with ADSCs (2×105) subcutaneously and intravenously, respectively. T-helper 17 (Th17) and regulatory T cell (Treg cell) of spleen cells were detected by flow cytometry. The levels of cytokines in the lung tissue and in the serum were detected by real-time fluorescence quantification. Real-time polymerase chain reaction(PCR) and enzyme-linked immuno sorbent assay(ELISA). The pathology change of skin and lung tissue was observed by hematoxylin eosin (HE) staining. RESULTS: The proportion of Th17 and Treg increased in BLM group than in control group(15.30%±1.29% vs.4.32%±0.79%; 9.90%±1.95% vs.5.18%±1.35%, P<0.05), the expression of Th17 significantly decreased (5.02%±0.83%, 6.00%±0.82% vs.15.30%±1.29%, P<0.05) and the expression of Treg increased after the ADSCs therapy (14.32%±1.59%, 11.09%±4.31% vs. 9.90%±1.95%, P<0.05). The expression levels of IL-17,IL-6,tumor necrosis factor-α (TNF-α)mRNA in the lung tissue and IL-6 in the serum increased in BLM group than in control group [3.54±0.30, 10.65±0.66, 5.37±0.52 vs. 1.00±0.00; (21.2±1.74) ng/L vs. (16.87±1.09) ng/L, P<0.05]. The expression of these cytokines significant decreased after the ADSCs therapy [1.63±0.45,1.50±0.29 vs.3.54±0.30; 3.11±0.85, 2.98±0.76 vs.10.65±0.66;1.45±0.47, 1.59±0.41 vs. 5.37±0.52; (17.87±1.45) ng/L, (17.61±1.16) ng/L vs. (21.2±1.74) ng/L, P<0.05]. But there was no obvious difference between ADSCs (hypodermic injection) group and ADSCs (intravenous injection) group(P>0.05). The expression of TGF-ß in the serum increased in BLM group than in control group[(33.95±2.49) ng/L vs. (28.8± 2.29) ng/L, P<0.05], however, the expression of TGF-ß mRNA had no significant differences than that of control group (1.17±0.11 vs.1.00±0.00, P>0.05). The expression of TGF-ß mRNA and protein had no significant differences than that of BLM group [1.25±0.11,1.26±0.12 vs.1.17±0.11; (31.84±2.04) ng/L, (31.25±2.36) ng/L vs. (33.95±2.49) ng/L, P>0.05]. HE staining showed that the inflammation of lung tissue was relieved and the dermal thickness and collagen deposition were decreased after the ADSCs therapy. CONCLUSION: ADSCs could effectively alleviate inflammation of the lungs and fibrosis of skin; the effects of anti-inflammatory and anti-fibrosis were associated with immune regulating function.

Respuesta de ratones Balb/c frente a ciclofosfamida y bleomicina en el ensayo cometa alcalino de linfocitos de sangre periférica / Balb/c mice response against cyclophosphamide and bleomycin in the alkaline comet assay of peripheral blood lymphocytes

En este artículo se evaluó el efecto mutágenico de la ciclofosfamida y bleomicina, con el objetivo de armonizar el número de exposiciones al ser utilizadas como controles positivos en ensayos in vivo de genotoxicidad, mediante el ensayo cometa alcalino. Se realizó en linfocitos de sangre periférica, utilizando 10 ratones/grupo/sexo de la línea Balb/c como biomodelo experimental. Fueron formados 5 grupos experimentales/sexo, el primero administrado con NaCl al 0,9% por vía intraperitoneal (i.p) como control negativo. El segundo y el tercero administrados con ciclofosfamida por vía i.p, con diseños de tratamientos diferentes en dosis de 50 mg/kg. El cuarto y quinto grupo fueron administrados con bleomicina por vía i.p, igualmente en dos diseños de tratamientos diferentes en dosis de 20 mg/kg. El mayor valor de inducción de daño se obtuvo con el uso de la ciclofosfamida y bleomicina, ambas en el diseño de administración de 48 y 24 horas antes de la eutanasia. Este estudio será aplicable a la evaluación de drogas que no han sido exploradas en el ámbito de la antigenotoxicidad y genotoxicidad in vivo. Además permitirá contar con un mayor conocimiento acerca de este ensayo, favoreciendo su validación (AU)

In this article were evaluated the mutagenic effect of cyclophosphamide and bleomycin, with the objective of harmonizing the number of exhibitions when being used as positive controls on in vivo genotoxicity assay, by means of alkaline comet assay. It was carried out in peripheral blood lymphocytes, using 10 mice/group/sex of the Balb/c line as experimental biomodel. We were formed 5 experimental groups per sex. The first group was administered with NaCl 0,9 % by intraperitoneal (i.p) route. The second and third groups were administered with cyclophosphamide by i.p route, with designs of different treatments at doses of 50 mg/kg. The fourth and fifth groups were administered with bleomycin by i.p route, equally in two designs of different treatments at doses of 20 mg/kg. The bigger inductions of damage were obtained with the use of the cyclophosphamide and bleomycin, both in the design of 48 and 24 hours administration before the euthanasia. This study will be applicable to the drugs evaluation that they have not been explored in to the in vivo antigenotoxicity and genotoxicity environment. It will also allow having a bigger knowledge about this assay, favoring their validation (AU)

Synthetic liposomes are protective from bleomycin-induced lung toxicity.

Idiopathic pulmonary fibrosis is a devastating disease characterized by a progressive, irreversible, and ultimately lethal form of lung fibrosis. Except for lung transplantation, no effective treatment options currently exist. The bleomycin animal model is one of the best studied models of lung injury and fibrosis. A previous study using mouse tumor models observed that liposome-encapsulated bleomycin exhibited reduced lung toxicity. Therefore, we hypothesized that airway delivery of synthetic phosphatidylcholine-containing liposomes alone would protect mice from bleomycin-induced lung toxicity. C57BL/6 mice were administered uncharged multilamellar liposomes (100 µl) or PBS vehicle on day 0 by airway delivery. Bleomycin (3.33 U/kg) or saline vehicle was then given intratracheally on day 1 followed by four additional separate doses of liposomes on days 4, 8, 12, and 16. Fluorescent images of liposomes labeled with 1,1'-dioctadecyl-3,3,3',3' tetramethylindocarbocyanine perchlorate confirmed effective and widespread delivery of liposomes to the lower respiratory tract as well as uptake primarily by alveolar macrophages and to a lesser extent by type II alveolar epithelial cells. Results at day 22, 3 wk after bleomycin treatment, showed that airway delivery of liposomes before and after intratracheal administration of bleomycin significantly reduced bleomycin-induced lung toxicity as evidenced by less body weight loss, chronic lung inflammation, and fibrosis as well as improved lung compliance compared with controls. These data indicate that airway-delivered synthetic liposomes represent a novel treatment strategy to reduce the lung toxicity associated with bleomycin in a mouse model.